Management of skin disease in patients with lupus erythematosus

被引:29
作者
Callen, JP [1 ]
机构
[1] Univ Louisville, Sch Med, Div Dermatol, Louisville, KY 40202 USA
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2002年 / 16卷 / 02期
关键词
discoid lupus erythematosus; subacute cutaneous LE; hypertrophic LE; lupus erythematosus panniculitis; antimalarial therapy; photosensitivity;
D O I
10.1053/berh.2001.0224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Skin disease in patients with lupus erythematosus may be subdivided into two broad categories - those represented by a 'specific' histopathology, the interface dermatitis, and those with changes that are not specific to lupus erythematosus, for example, vasculitis, mucin infiltration, etc. The specific skin lesions that are most common are discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). Evaluation will allow the treating physician to assign a prognosis. Cutaneous lesions can generally be managed with standard therapies. Patients with discoid LE and subacute cutaneous LE are generally photosensitive, and therefore sunscreens, protective clothing and behavioural alteration should be discussed with all patients. Topical corticosteroids are a standard form of therapy, but 'newer' agents such as retinoids, calcipotriene and tacrolimus might be effective. Antimalarial agents are generally effective. Attempts to reduce or stop smoking may aid in the control of cutaneous LE. The choice of alternative therapy is personal, and discussions of the risks and benefits should be carefully documented.
引用
收藏
页码:245 / 264
页数:20
相关论文
共 53 条
[1]   The anti-phospholipid antibody syndrome:: clinical and serological aspects [J].
Alarcón-Segovia, D ;
Cabral, AR .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2000, 14 (01) :139-150
[2]  
ATRA E, 1993, CLIN EXP RHEUMATOL, V11, P487
[3]   Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms [J].
Boehm, IB ;
Boehm, GA ;
Bauer, R .
RHEUMATOLOGY INTERNATIONAL, 1998, 18 (02) :59-62
[4]   Terbinafine-induced subacute cutaneous lupus erythematosus [J].
Bonsmann, G ;
Schiller, M ;
Luger, TA ;
Ständer, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (06) :925-931
[6]   AZATHIOPRINE - AN EFFECTIVE, CORTICOSTEROID-SPARING THERAPY FOR PATIENTS WITH RECALCITRANT CUTANEOUS LUPUS-ERYTHEMATOSUS OR WITH RECALCITRANT CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS [J].
CALLEN, JP ;
SPENCER, LV ;
BURRUSS, JB ;
HOLTMAN, J .
ARCHIVES OF DERMATOLOGY, 1991, 127 (04) :515-522
[7]   SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS - CLINICAL, SEROLOGIC, IMMUNOGENETIC, AND THERAPEUTIC CONSIDERATIONS IN 72 PATIENTS [J].
CALLEN, JP ;
KLEIN, J .
ARTHRITIS AND RHEUMATISM, 1988, 31 (08) :1007-1013
[8]  
CALLEN JP, 1988, RHEUM DIS CLIN N AM, V14, P79
[9]   Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognised [J].
Callen, JP .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (02) :315-316
[10]  
CALLEN JP, 2001, DERMATOLOGIC THERAPY, V14, P61